Tailored immunotherapy cocktail shows promise for tough stomach cancer
NCT ID NCT04739202
First seen Jun 10, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while others got atezolizumab plus bevacizumab. The goal was to see if tailoring therapy could improve response rates in this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aphm - Hopital La Timone
Marseille, 13385, France
-
Aphp - Hopital Pitie Salpetriere
Paris, 75013, France
-
Aphp - Hopital Saint-Louis
Paris, 75010, France
-
Bordeaux - Hopital Haut-Leveque
Pessac, 33604, France
-
Dijon - Centre Georges-Francois Leclerc
Dijon, 21000, France
-
Hcl - Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Hcl - Hopital Edouard Herriot
Lyon, 69003, France
-
Toulouse - Iuct Rangueil-Larrey
Toulouse, 31059, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab combined with either Ipatasertib or Bevacizumab
What this could lead to
If successful, this approach could lead to more effective, personalized treatment options for advanced gastric cancer patients who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial with only 54 participants, so results may not apply to all patients. The combinations may cause side effects or fail to improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.